Cizzle Biotechnology Holdings plc
("Cizzle Biotechnology", or the "Company")
Notice of Annual General Meeting
Cizzle Biotechnology, the UK based diagnostics developer , announces that the notice of Annual General Meeting ("AGM"), has been sent to shareholders and is available for viewing on the Company's website at https://cizzlebiotechnology.com .
The AGM will be held at 11.00 a.m. on 24 June 2024 at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
| Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
| Allan Syms (Executive Chairman) |
|
| Allenby Capital Limited |
+44(0) 20 3328 5656 |
|
| John Depasquale |
|
|
| George Payne |
|
|
| Novum Securities Limited |
+44(0) 20 7399 9400 |
| Colin Rowbury Jon Bellis |
|
| IFC Advisory Limited |
+44(0) 20 3934 6630 |
| Tim Metcalfe |
|
| Florence Chandler |
|
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test to facilitate the early detection of lung cancer based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant has been shown to be highly correlated with early-stage lung cancer. The Company's proprietary technology results from the work of Professor Coverley and colleagues at the University of York.
For more information please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.